Atea (AVIR) Q2 2026 Earnings Call Summary
During Atea's second-quarter earnings call for fiscal year 2026, the company reported a net loss of $32.9 million or $0.41 per share and cash reserves of $219.5 million as of June 30, down from $301.8 million at the end of 2025. Management expects these funds to last through 2027, supporting ongoing Phase 3 trials for its lead candidate bemnifosbuvir/ruzasvir (BEM/RZR) and prelaunch activities. The C-BEYOND trial met primary endpoints with a sustained virologic response rate of 93.9% at week 24, showing non-inferiority to Epclusa in treating hepatitis C virus (HCV). The company also highlighted strong performance across treatment groups for cirrhotic and non-cirrhotic patients. Atea plans an NDA submission by Q2 2027 if the global Phase 3 trial, C-FORWARD, delivers positive results early next year. The firm is preparing a commercial launch in mid-2028 with a targeted sales force of up to 100 specialists. Management estimates peak U.S. net revenue could exceed $700 million annually based on the growing gap between HCV infections and cures.
Topics: cash_flow clinical_trials pharmaceuticals research_development